Cymabay Therapeu Correlations
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
The current 90-days correlation between Cymabay Therapeu and Akero Therapeutics is -0.03 (i.e., Good diversification). The correlation of Cymabay Therapeu is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Cymabay Therapeu Correlation With Market
Modest diversification
The correlation between Cymabay Therapeu and DJI is 0.21 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cymabay Therapeu and DJI in the same portfolio, assuming nothing else is changed.
Cymabay |
Moving together with Cymabay Stock
Moving against Cymabay Stock
| 0.56 | PBCRY | Bank Central Asia | PairCorr |
| 0.47 | PTAIY | Astra International Tbk | PairCorr |
| 0.34 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.31 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cymabay Stock performing well and Cymabay Therapeu Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cymabay Therapeu's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | 2.03 | (0.05) | (0.03) | 0.05 | 2.73 | 3.84 | 11.44 | |||
| XFOR | 5.11 | (0.54) | 0.00 | (0.26) | 0.00 | 8.82 | 62.35 | |||
| INZY | 2.78 | (1.17) | 0.00 | (0.60) | 0.00 | 5.07 | 16.62 | |||
| ABOS | 3.58 | (0.48) | 0.00 | (0.06) | 0.00 | 7.52 | 28.07 | |||
| MREO | 2.71 | (0.43) | 0.00 | (0.26) | 0.00 | 4.80 | 17.36 | |||
| AKRO | 2.37 | 0.09 | 0.06 | 0.16 | 2.63 | 5.23 | 13.37 | |||
| TERN | 3.38 | (0.34) | 0.00 | (0.23) | 0.00 | 6.02 | 34.09 | |||
| MDGL | 2.72 | 0.42 | 0.14 | 1.28 | 2.17 | 5.17 | 30.27 | |||
| VKTX | 3.52 | (0.34) | 0.00 | (0.13) | 0.00 | 6.24 | 34.61 | |||
| BMEA | 3.45 | (0.06) | (0.02) | 0.04 | 4.69 | 9.12 | 24.44 |
View Cymabay Therapeu Related Equities
| Risk & Return | Correlation |
Cymabay Therapeu Corporate Management
| BA BA | Chief Officer | Profile | |
| Paul Quinlan | General Counsel, Corporate Secretary | Profile | |
| Patrick OMara | Senior Development | Profile | |
| Robert Martin | Senior Development | Profile | |
| Klara DickinsonEason | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
Still Interested in Cymabay Therapeu?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.